As of October 22, 2026, Regencell Bioscience Holdings Ltd (RGC) trades at $10.00. No model fair value is published for RGC. Equity Rank publishes a blended model fair value only when enough valuation methods have usable data and pass its reliability checks. For RGC they currently do not (common causes are losses or negative cash flow, too little reporting history, or methods that disagree too widely), so no fair value is shown.
Source: Equity Rank — RGC valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Regencell Bioscience Holdings Ltd (RGC) is next scheduled to report earnings on Oct 30, 2026.
Reported EPS came in above the analyst estimate in 0 of the last 8 reports. The median share-price change across a report, in either direction, was 2.8%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Oct 24, 2025 | $0.00 | $0.00 | — | — |
| Jun 26, 2025 | $0.00 | $0.00 | — | -7.1% |
| Oct 25, 2024 | $0.00 | $0.00 | — | +1.5% |
| Oct 31, 2022 | $0.00 | $-0.30 | — | -7.3% |
| Jun 2, 2022 | $0.00 | $-0.29 | — | +2.8% |
| Oct 29, 2021 | $0.00 | $-0.11 | — | -2.7% |
| Apr 26, 2021 | $0.00 | $-33.38 | — | — |
| Mar 31, 2021 | $0.00 | $-0.05 | — | — |
Equity Rank's fundamental strength composite scores RGC at 36.8/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality. Its SAVE composite score has moved +1.3 over the past 30 days.
Equity Rank publishes a blended model fair value only when enough valuation methods have usable data and pass its reliability checks. For RGC they currently do not (common causes are losses or negative cash flow, too little reporting history, or methods that disagree too widely), so no fair value is shown. Informational only — not investment advice.
Regencell Bioscience Holdings Ltd (RGC) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Regencell Bioscience Holdings Ltd (RGC) is classified in the Pharmaceuticals sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Specialty & Generic Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/RGC. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.